Group 1 - The core viewpoint of the news is that 开拓药业-B (09939) has seen a significant stock price increase of over 8% following the announcement of the completion of human safety trials for its new tyrosinase inhibitor, KT-939, which effectively inhibits melanin production [1][2] - KT-939 has completed enrollment of 130 participants in its long-term safety trial and has shown promising results in both efficacy and safety during previous assessments [1] - The company plans to submit a registration application for KT-939 to the Chinese drug regulatory authority in the third quarter of next year, aiming to become the first domestically developed whitening cosmetic ingredient approved in China [2] Group 2 - KT-939 is designed to precisely target tyrosinase, blocking the oxidation process of tyrosine, and has demonstrated antioxidant and anti-inflammatory properties, providing significant advantages in cosmetic efficacy and safety [1] - The approval of a similar tyrosinase inhibitor, Thiamidol, in November 2024 marks a milestone as the first and only newly registered whitening cosmetic ingredient since the implementation of the 2021 Cosmetics Supervision and Administration Regulations in China [2] - The successful registration of KT-939 would represent a breakthrough in China's independent intellectual property rights in the field of whitening agents, offering new options for the global skin whitening market [2]